Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
CCMI is a positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptors (nAChRs).1 It enhances ACh-, nicotine-, or choline-induced currents in Xenopus oocytes expressing recombinant human α7 nAChRs (EC50s = 0.7, 0.6, and 0.5 µM, respectively). In vivo, CCMI (0.3 and 1 mg/kg, i.v.) improves sensory gating deficits in a paired auditory stimulus paradigm in mice. It decreases the latency to find the platform in the Morris water maze test in a rat model of traumatic brain injury (TBI) induced by parasagittal fluid-percussion.2
WARNING This product is not for human or veterinary use.
1. Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. USA 104(19), 8058-8064 (2023).
2. Positive allosteric modulation of the α7 nicotinic acetylcholine receptor as a treatment for cognitive deficits after traumatic brain injury. PLoS One 14(10), e0223180 (2019).